Genomic and nongenomic effects of glucocorticoids (Q34819002)

4 August 2017

1 reference

title

Genomic and nongenomic effects of glucocorticoids (English)

1 reference

4 August 2017

2

Frank Buttgereit

0 references

author name string

Cindy Stahn

series ordinal

1

1 reference

4 August 2017

publication date

2 September 2008

1 reference

Nature Clinical Practice Rheumatology

4 August 2017

published in

1 reference

4 August 2017

volume

4

1 reference

4 August 2017

issue

10

1 reference

4 August 2017

page(s)

525-533

1 reference

Optimised glucocorticoid therapy: the sharpening of an old spear

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

The hsp90-based Chaperone System: Involvement in Signal Transduction from a Variety of Hormone and Growth Factor Receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

Direct interaction of the tau 1 transactivation domain of the human glucocorticoid receptor with the basal transcriptional machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

Glucocorticoid receptor nitration leads to enhanced anti-inflammatory effects of novel steroid ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

Current use of glucocorticoids in patients with rheumatoid arthritis in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

Are Glucocorticoids DMARDs?

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

The molecular basis for the effectiveness, toxicity, and resistance to glucocorticoids: focus on the treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data.

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

Oral corticosteroids and fracture risk: relationship to daily and cumulative doses

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

Revisiting the toxicity of low-dose glucocorticoids: risks and fears

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

Mechanisms involved in the side effects of glucocorticoids

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

Corticosteroid-insensitive asthma: molecular mechanisms.

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

Glucocorticoid action and novel mechanisms of steroid resistance: role of glucocorticoid receptor-interacting proteins for glucocorticoid responsiveness

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

Rapid glucocorticoid effects on immune cells

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

Novel insights into mechanisms of glucocorticoid action and the development of new glucocorticoid receptor ligands

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

Primary structure and expression of a functional human glucocorticoid receptor cDNA

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

The origin and functions of multiple human glucocorticoid receptor isoforms

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

Mechanisms of Corticosteroid Resistance in Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

The dominant negative activity of the human glucocorticoid receptor beta isoform. Specificity and mechanisms of action

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

Mouse glucocorticoid receptor phosphorylation status influences multiple functions of the receptor protein

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

Structural characterization of a minimal functional transactivation domain from the human glucocorticoid receptor

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

Steroid hormone receptors: an update

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

Chaperoning of glucocorticoid receptors

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

Zap70 signaling pathway mediates glucocorticoid receptor-dependent transcriptional activation: role in the regulation of annexin 1 expression in T cells

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

Hormone-mediated repression: a negative glucocorticoid response element from the bovine prolactin gene

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

Glucocorticoids repress NF-kappaB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

The glucocorticoid receptor inhibits NFkappaB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

Insight into the molecular mechanisms of glucocorticoid receptor action promotes identification of novel ligands with an improved therapeutic index.

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

The effects of non-genomic glucocorticoid mechanisms on bodily functions and the central neural system. A critical evaluation of findings.

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

Glucocorticoids act within minutes to inhibit recruitment of signalling factors to activated EGF receptors through a receptor-dependent, transcription-independent mechanism

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

Bioenergetics of immune functions: fundamental and therapeutic aspects

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

The plasma membrane estrogen receptor: nuclear or unclear?

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

Plasma membrane-resident glucocorticoid receptors in rodent lymphoma and human leukemia models

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

A corticosteroid receptor in neuronal membranes

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

Membrane glucocorticoid receptors (mGCR) are expressed in normal human peripheral blood mononuclear cells and up-regulated after in vitro stimulation and in patients with rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

Non-genomic glucocorticoid effects to provide the basis for new drug developments

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

Membrane glucocorticoid receptors are down regulated by glucocorticoids in patients with systemic lupus erythematosus and use a caveolin-1-independent expression pathway

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

Rapid immunosuppressive effects of glucocorticoids mediated through Lck and Fyn.

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

Glucocorticoids cause rapid dissociation of a T-cell-receptor-associated protein complex containing LCK and FYN

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

Generation of innovative anti-inflammatory and anti-arthritic glucocorticoid derivatives that release NO: the nitro-steroids

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

Potent antiarthritic properties of a glucocorticoid derivative, NCX-1015, in an experimental model of arthritis

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index.

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

trans-Activation and repression properties of the novel nonsteroid glucocorticoid receptor ligand 2,5-dihydro-9-hydroxy-10-methoxy-2,2,4-trimethyl-5-(1-methylcyclohexen-3-y1)-1H-[1]benzopyrano[3,4-f]quinoline (A276575) and its four stereoisomers

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein-protein interaction profile

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

LGD-5552, an antiinflammatory glucocorticoid receptor ligand with reduced side effects, in vivo

1 reference

https://api.crossref.org/works/10.1038/NCPRHEUM0898

7 January 2021

Identifiers

DOI

10.1038/NCPRHEUM0898

1 reference

release_iw3cpsspbrhyjnpgzlgcv32vtm

4 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/iw3cpsspbrhyjnpgzlgcv32vtm

24 November 2022

mapped directly with Wikidata item

1 reference